Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia-Reference-Cited by-同舟云学术

Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia

Published:2020-07-22 Issue:8 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Tannous Elias¹²,Lipman Shelly³,Tonna Antonella⁴,Hector Emma⁴,Hussein Ziad⁵,Stein Michal³⁶,Reisfeld Sharon³⁶^ORCID

Affiliation:

1. Pharmacy, Hillel Yaffe Medical Center, Hadera, Israel

2. Ben Gurion University, Beersheba, Israel

3. Infectious Diseases Unit, Hillel Yaffe Medical Center, Hadera, Israel

4. Robert Gordon University, School of Pharmacy and Life Sciences, Aberdeen, Scotland

5. Clinical Pharmacology Science, Eisai Ltd., Hatfield, United Kingdom

6. The Ruth & Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

Abstract

Pseudomonas aeruginosa bacteremia is an infection associated with a high mortality rate. Piperacillin-tazobactam is a β-lactam–β-lactamase inhibitor combination that is frequently used for the management of Pseudomonas aeruginosa infections. The pharmacokinetic-pharmacodynamic index associated with in vitro maximal bacterial killing for piperacillin-tazobactam is the percentage of the time between doses at which the free fraction concentration remains above the MIC (% fT >MIC ).

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02571-19

Reference35 articles.

1. Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study

2. Pseudomonas aeruginosa Serious Infections: Mono or Combination Antimicrobial Therapy?

3. Bennett JE, Dolin R, Blaser MJ. 2015. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, 8th ed. Saunders, Philadelphia, PA.

4. A model to predict mortality following Pseudomonas aeruginosa bacteremia

5. Pseudomonas bacteremia. Retrospective analysis of 410 episodes

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing;Clinical Microbiology Reviews;2024-06-13

2. Multistate modeling for survival analysis in critically ill patients treated with meropenem;CPT: Pharmacometrics & Systems Pharmacology;2023-11-07

3. Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting;Intensive Care Medicine;2023-07-13

4. Evaluation of continuous ampicillin/sulbactam infusion in critically ill patients;Life Sciences;2023-05

5. Piperacillin Steady State Concentrations in Target Tissues Relevant for PJI Treatment—A Randomized Porcine Microdialysis Study Comparing Continuous Infusion with Intermittent Short-Term Infusion;Antibiotics;2023-03-14